Skip to main content

Table 1 Demographic, clinical course and outcome data of patients who acquired SBIs during the COVID-19 hospitalization

From: Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

  All patients (n = 102) Severe group (n = 33) Critical group (n = 69) P-value
Characteristics
 Age, years 66.2 (30 ~ 93) 64.9 (30 ~ 82) 66.1 (36 ~ 93) 0.686
 Sex 0.178
  Men 68 (66.7%) 19 (57.6%) 49 (71.0%)  
  Women 34 (33.3%) 14 (42.4%) 20 (29.0%)
Bacterial etiology
A. baumanniia 50 (49.0%) 10 (30.3%) 40 (58.0%) 0.009
CRABa 47 (46.1%) 9 (27.3%) 38 (55.1%) 0.008
K. pneumoniaea 35 (34.3%) 6 (18.2%) 29 (42.0%) 0.018
CRKPa 32 (31.4%) 5 (15.2%) 27 (39.1%) 0.015
Treatment before SBIs
 Antiviral therapy 96 (94.1%) 29 (87.9%) 67 (97.1%) 0.084
 Antibiotic therapy 99 (97.1%) 31 (93.9%) 68 (98.6%) 0.244
Outcomes < 0.0001
 Discharge 52 (51.0%) 28 (84.8%) 24 (34.8%)  
 Death 50 (49.0%) 5 (15.2%) 45 (65.2%)
  1. Data are median (IQR) or n (%). P values comparing severe group and critical group are from Mann-Whitney U test, χ2 test, or Fisher’s exact test
  2. aNumber of patients suffering from a certain bacterial infection